nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—HRH2—gastric juice—pancreatic cancer	0.138	0.838	CbGeAlD
Famotidine—HRH2—Secretion of Hydrochloric Acid in Parietal Cells—CCKBR—pancreatic cancer	0.025	0.195	CbGpPWpGaD
Famotidine—HRH2—Secretion of Hydrochloric Acid in Parietal Cells—GAST—pancreatic cancer	0.0215	0.167	CbGpPWpGaD
Famotidine—HRH2—digestive system—pancreatic cancer	0.00842	0.0511	CbGeAlD
Famotidine—SLC22A2—digestive system—pancreatic cancer	0.00768	0.0466	CbGeAlD
Famotidine—SLC47A1—digestive system—pancreatic cancer	0.0065	0.0394	CbGeAlD
Famotidine—CYP2C19—digestive system—pancreatic cancer	0.00418	0.0254	CbGeAlD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00342	0.0266	CbGpPWpGaD
Famotidine—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.00284	0.0221	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.00213	0.0166	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.00174	0.0135	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00161	0.0125	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—SCT—pancreatic cancer	0.00156	0.0122	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—GLP1R—pancreatic cancer	0.00145	0.0113	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.00141	0.0109	CbGpPWpGaD
Famotidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.00134	0.0104	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.00129	0.0101	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—IAPP—pancreatic cancer	0.00129	0.01	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—PTHLH—pancreatic cancer	0.00123	0.00961	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.0012	0.00938	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.0012	0.00931	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.00115	0.00892	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00112	0.00872	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.0011	0.00859	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.00107	0.0083	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00102	0.00798	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—GCG—pancreatic cancer	0.00101	0.00783	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.001	0.00781	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.000982	0.00765	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.000963	0.0075	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.000945	0.00736	CbGpPWpGaD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.000931	0.00725	CbGpPWpGaD
Famotidine—Insomnia—Fluorouracil—pancreatic cancer	0.000926	0.00131	CcSEcCtD
Famotidine—Somnolence—Gemcitabine—pancreatic cancer	0.000925	0.00131	CcSEcCtD
Famotidine—Migraine—Doxorubicin—pancreatic cancer	0.000923	0.00131	CcSEcCtD
Famotidine—Fatigue—Irinotecan—pancreatic cancer	0.000921	0.0013	CcSEcCtD
Famotidine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000919	0.0013	CcSEcCtD
Famotidine—Alopecia—Docetaxel—pancreatic cancer	0.000919	0.0013	CcSEcCtD
Famotidine—Pruritus—Sunitinib—pancreatic cancer	0.000918	0.0013	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—PRLHR—pancreatic cancer	0.000917	0.00714	CbGpPWpGaD
Famotidine—Pain—Irinotecan—pancreatic cancer	0.000914	0.00129	CcSEcCtD
Famotidine—Constipation—Irinotecan—pancreatic cancer	0.000914	0.00129	CcSEcCtD
Famotidine—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000913	0.00129	CcSEcCtD
Famotidine—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000913	0.00129	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.000913	0.00711	CbGpPWpGaD
Famotidine—Mental disorder—Docetaxel—pancreatic cancer	0.000911	0.00129	CcSEcCtD
Famotidine—Somnolence—Fluorouracil—pancreatic cancer	0.00091	0.00129	CcSEcCtD
Famotidine—Face oedema—Doxorubicin—pancreatic cancer	0.000906	0.00128	CcSEcCtD
Famotidine—Decreased appetite—Gemcitabine—pancreatic cancer	0.000905	0.00128	CcSEcCtD
Famotidine—Dyspepsia—Fluorouracil—pancreatic cancer	0.000901	0.00127	CcSEcCtD
Famotidine—Nausea—Tamoxifen—pancreatic cancer	0.0009	0.00127	CcSEcCtD
Famotidine—Fatigue—Gemcitabine—pancreatic cancer	0.000897	0.00127	CcSEcCtD
Famotidine—Pain—Gemcitabine—pancreatic cancer	0.00089	0.00126	CcSEcCtD
Famotidine—Constipation—Gemcitabine—pancreatic cancer	0.00089	0.00126	CcSEcCtD
Famotidine—Nausea—Erlotinib—pancreatic cancer	0.00089	0.00126	CcSEcCtD
Famotidine—Decreased appetite—Fluorouracil—pancreatic cancer	0.00089	0.00126	CcSEcCtD
Famotidine—Diarrhoea—Sunitinib—pancreatic cancer	0.000888	0.00126	CcSEcCtD
Famotidine—Dysgeusia—Docetaxel—pancreatic cancer	0.000886	0.00125	CcSEcCtD
Famotidine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000881	0.00125	CcSEcCtD
Famotidine—Influenza—Epirubicin—pancreatic cancer	0.000876	0.00124	CcSEcCtD
Famotidine—Back pain—Docetaxel—pancreatic cancer	0.000875	0.00124	CcSEcCtD
Famotidine—Pain—Fluorouracil—pancreatic cancer	0.000875	0.00124	CcSEcCtD
Famotidine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000874	0.00124	CcSEcCtD
Famotidine—Muscle spasms—Docetaxel—pancreatic cancer	0.00087	0.00123	CcSEcCtD
Famotidine—Dry skin—Doxorubicin—pancreatic cancer	0.00086	0.00122	CcSEcCtD
Famotidine—Dizziness—Sunitinib—pancreatic cancer	0.000858	0.00121	CcSEcCtD
Famotidine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000858	0.00121	CcSEcCtD
Famotidine—Body temperature increased—Irinotecan—pancreatic cancer	0.000845	0.0012	CcSEcCtD
Famotidine—Abdominal pain—Irinotecan—pancreatic cancer	0.000845	0.0012	CcSEcCtD
Famotidine—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000845	0.0012	CcSEcCtD
Famotidine—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000845	0.0012	CcSEcCtD
Famotidine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000843	0.00119	CcSEcCtD
Famotidine—Bronchitis—Epirubicin—pancreatic cancer	0.000843	0.00119	CcSEcCtD
Famotidine—Anaemia—Docetaxel—pancreatic cancer	0.000837	0.00118	CcSEcCtD
Famotidine—Pancytopenia—Epirubicin—pancreatic cancer	0.000832	0.00118	CcSEcCtD
Famotidine—Vomiting—Sunitinib—pancreatic cancer	0.000825	0.00117	CcSEcCtD
Famotidine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000823	0.00116	CcSEcCtD
Famotidine—Dysuria—Epirubicin—pancreatic cancer	0.000819	0.00116	CcSEcCtD
Famotidine—Neutropenia—Epirubicin—pancreatic cancer	0.000819	0.00116	CcSEcCtD
Famotidine—Rash—Sunitinib—pancreatic cancer	0.000818	0.00116	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000818	0.00637	CbGpPWpGaD
Famotidine—Dermatitis—Sunitinib—pancreatic cancer	0.000817	0.00116	CcSEcCtD
Famotidine—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000814	0.00115	CcSEcCtD
Famotidine—Urticaria—Fluorouracil—pancreatic cancer	0.000813	0.00115	CcSEcCtD
Famotidine—Headache—Sunitinib—pancreatic cancer	0.000813	0.00115	CcSEcCtD
Famotidine—Syncope—Docetaxel—pancreatic cancer	0.000812	0.00115	CcSEcCtD
Famotidine—Influenza—Doxorubicin—pancreatic cancer	0.000811	0.00115	CcSEcCtD
Famotidine—Leukopenia—Docetaxel—pancreatic cancer	0.00081	0.00115	CcSEcCtD
Famotidine—Pollakiuria—Epirubicin—pancreatic cancer	0.000809	0.00115	CcSEcCtD
Famotidine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000809	0.00114	CcSEcCtD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.000807	0.00629	CbGpPWpGaD
Famotidine—Palpitations—Docetaxel—pancreatic cancer	0.0008	0.00113	CcSEcCtD
Famotidine—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.0008	0.00113	CcSEcCtD
Famotidine—Loss of consciousness—Docetaxel—pancreatic cancer	0.000795	0.00113	CcSEcCtD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.000794	0.00619	CbGpPWpGaD
Famotidine—Cough—Docetaxel—pancreatic cancer	0.00079	0.00112	CcSEcCtD
Famotidine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000787	0.00111	CcSEcCtD
Famotidine—Convulsion—Docetaxel—pancreatic cancer	0.000784	0.00111	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—SSTR3—pancreatic cancer	0.00078	0.00607	CbGpPWpGaD
Famotidine—Bronchitis—Doxorubicin—pancreatic cancer	0.00078	0.0011	CcSEcCtD
Famotidine—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000774	0.0011	CcSEcCtD
Famotidine—Myalgia—Docetaxel—pancreatic cancer	0.000771	0.00109	CcSEcCtD
Famotidine—Chest pain—Docetaxel—pancreatic cancer	0.000771	0.00109	CcSEcCtD
Famotidine—Arthralgia—Docetaxel—pancreatic cancer	0.000771	0.00109	CcSEcCtD
Famotidine—Nausea—Sunitinib—pancreatic cancer	0.000771	0.00109	CcSEcCtD
Famotidine—Pancytopenia—Doxorubicin—pancreatic cancer	0.00077	0.00109	CcSEcCtD
Famotidine—Asthenia—Irinotecan—pancreatic cancer	0.000767	0.00108	CcSEcCtD
Famotidine—Jaundice—Epirubicin—pancreatic cancer	0.000761	0.00108	CcSEcCtD
Famotidine—Dysuria—Doxorubicin—pancreatic cancer	0.000758	0.00107	CcSEcCtD
Famotidine—Neutropenia—Doxorubicin—pancreatic cancer	0.000758	0.00107	CcSEcCtD
Famotidine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000754	0.00107	CcSEcCtD
Famotidine—Dry mouth—Docetaxel—pancreatic cancer	0.000754	0.00107	CcSEcCtD
Famotidine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000753	0.00107	CcSEcCtD
Famotidine—Pollakiuria—Doxorubicin—pancreatic cancer	0.000749	0.00106	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—SSTR1—pancreatic cancer	0.000748	0.00582	CbGpPWpGaD
Famotidine—Asthenia—Gemcitabine—pancreatic cancer	0.000747	0.00106	CcSEcCtD
Famotidine—Haematuria—Epirubicin—pancreatic cancer	0.000745	0.00105	CcSEcCtD
Famotidine—Confusional state—Docetaxel—pancreatic cancer	0.000745	0.00105	CcSEcCtD
Famotidine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.00074	0.00105	CcSEcCtD
Famotidine—Oedema—Docetaxel—pancreatic cancer	0.000739	0.00105	CcSEcCtD
Famotidine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000739	0.00105	CcSEcCtD
Famotidine—Pruritus—Gemcitabine—pancreatic cancer	0.000736	0.00104	CcSEcCtD
Famotidine—Infection—Docetaxel—pancreatic cancer	0.000734	0.00104	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—PPY—pancreatic cancer	0.000733	0.00571	CbGpPWpGaD
Famotidine—Sinusitis—Epirubicin—pancreatic cancer	0.000733	0.00104	CcSEcCtD
Famotidine—Diarrhoea—Irinotecan—pancreatic cancer	0.000731	0.00103	CcSEcCtD
Famotidine—Agranulocytosis—Epirubicin—pancreatic cancer	0.000729	0.00103	CcSEcCtD
Famotidine—Shock—Docetaxel—pancreatic cancer	0.000727	0.00103	CcSEcCtD
Famotidine—Pruritus—Fluorouracil—pancreatic cancer	0.000724	0.00102	CcSEcCtD
Famotidine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000723	0.00102	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—SSTR2—pancreatic cancer	0.00072	0.0056	CbGpPWpGaD
Famotidine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000717	0.00101	CcSEcCtD
Famotidine—Bradycardia—Epirubicin—pancreatic cancer	0.000714	0.00101	CcSEcCtD
Famotidine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000712	0.00101	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00071	0.00553	CbGpPWpGaD
Famotidine—Dizziness—Irinotecan—pancreatic cancer	0.000707	0.001	CcSEcCtD
Famotidine—Jaundice—Doxorubicin—pancreatic cancer	0.000705	0.000997	CcSEcCtD
Famotidine—Anorexia—Docetaxel—pancreatic cancer	0.000704	0.000996	CcSEcCtD
Famotidine—Hepatitis—Epirubicin—pancreatic cancer	0.000701	0.000992	CcSEcCtD
Famotidine—Diarrhoea—Fluorouracil—pancreatic cancer	0.0007	0.000991	CcSEcCtD
Famotidine—SLC22A2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000698	0.00544	CbGpPWpGaD
Famotidine—Pharyngitis—Epirubicin—pancreatic cancer	0.000696	0.000985	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—CCKBR—pancreatic cancer	0.000695	0.00541	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.000692	0.00539	CbGpPWpGaD
Famotidine—Haematuria—Doxorubicin—pancreatic cancer	0.000689	0.000975	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00068	0.0053	CbGpPWpGaD
Famotidine—Vomiting—Irinotecan—pancreatic cancer	0.000679	0.000961	CcSEcCtD
Famotidine—Sinusitis—Doxorubicin—pancreatic cancer	0.000678	0.00096	CcSEcCtD
Famotidine—Dizziness—Fluorouracil—pancreatic cancer	0.000677	0.000958	CcSEcCtD
Famotidine—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000675	0.000954	CcSEcCtD
Famotidine—Rash—Irinotecan—pancreatic cancer	0.000674	0.000953	CcSEcCtD
Famotidine—Dermatitis—Irinotecan—pancreatic cancer	0.000673	0.000952	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000673	0.000952	CcSEcCtD
Famotidine—Headache—Irinotecan—pancreatic cancer	0.000669	0.000947	CcSEcCtD
Famotidine—CYP2C19—Melatonin metabolism and effects—APOE—pancreatic cancer	0.000669	0.00521	CbGpPWpGaD
Famotidine—Insomnia—Docetaxel—pancreatic cancer	0.000668	0.000945	CcSEcCtD
Famotidine—Paraesthesia—Docetaxel—pancreatic cancer	0.000663	0.000939	CcSEcCtD
Famotidine—Erythema multiforme—Epirubicin—pancreatic cancer	0.000663	0.000938	CcSEcCtD
Famotidine—Vomiting—Gemcitabine—pancreatic cancer	0.000662	0.000936	CcSEcCtD
Famotidine—Bradycardia—Doxorubicin—pancreatic cancer	0.000661	0.000935	CcSEcCtD
Famotidine—Somnolence—Docetaxel—pancreatic cancer	0.000657	0.000929	CcSEcCtD
Famotidine—Rash—Gemcitabine—pancreatic cancer	0.000656	0.000929	CcSEcCtD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000656	0.00511	CbGpPWpGaD
Famotidine—Dermatitis—Gemcitabine—pancreatic cancer	0.000656	0.000928	CcSEcCtD
Famotidine—Tinnitus—Epirubicin—pancreatic cancer	0.000654	0.000925	CcSEcCtD
Famotidine—Headache—Gemcitabine—pancreatic cancer	0.000652	0.000923	CcSEcCtD
Famotidine—Flushing—Epirubicin—pancreatic cancer	0.000651	0.000921	CcSEcCtD
Famotidine—Vomiting—Fluorouracil—pancreatic cancer	0.000651	0.000921	CcSEcCtD
Famotidine—Dyspepsia—Docetaxel—pancreatic cancer	0.00065	0.00092	CcSEcCtD
Famotidine—Hepatitis—Doxorubicin—pancreatic cancer	0.000649	0.000918	CcSEcCtD
Famotidine—Rash—Fluorouracil—pancreatic cancer	0.000645	0.000913	CcSEcCtD
Famotidine—Dermatitis—Fluorouracil—pancreatic cancer	0.000645	0.000912	CcSEcCtD
Famotidine—Pharyngitis—Doxorubicin—pancreatic cancer	0.000644	0.000911	CcSEcCtD
Famotidine—Decreased appetite—Docetaxel—pancreatic cancer	0.000642	0.000909	CcSEcCtD
Famotidine—Headache—Fluorouracil—pancreatic cancer	0.000641	0.000907	CcSEcCtD
Famotidine—Fatigue—Docetaxel—pancreatic cancer	0.000637	0.000901	CcSEcCtD
Famotidine—Nausea—Irinotecan—pancreatic cancer	0.000635	0.000898	CcSEcCtD
Famotidine—Pain—Docetaxel—pancreatic cancer	0.000632	0.000894	CcSEcCtD
Famotidine—Constipation—Docetaxel—pancreatic cancer	0.000632	0.000894	CcSEcCtD
Famotidine—Arrhythmia—Epirubicin—pancreatic cancer	0.000626	0.000886	CcSEcCtD
Famotidine—Alopecia—Epirubicin—pancreatic cancer	0.00062	0.000877	CcSEcCtD
Famotidine—Nausea—Gemcitabine—pancreatic cancer	0.000618	0.000875	CcSEcCtD
Famotidine—Mental disorder—Epirubicin—pancreatic cancer	0.000614	0.000869	CcSEcCtD
Famotidine—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000614	0.000868	CcSEcCtD
Famotidine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000609	0.000861	CcSEcCtD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000608	0.00474	CbGpPWpGaD
Famotidine—Nausea—Fluorouracil—pancreatic cancer	0.000608	0.00086	CcSEcCtD
Famotidine—Tinnitus—Doxorubicin—pancreatic cancer	0.000605	0.000856	CcSEcCtD
Famotidine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000604	0.000855	CcSEcCtD
Famotidine—Flushing—Doxorubicin—pancreatic cancer	0.000602	0.000852	CcSEcCtD
Famotidine—Dysgeusia—Epirubicin—pancreatic cancer	0.000598	0.000846	CcSEcCtD
Famotidine—Back pain—Epirubicin—pancreatic cancer	0.000591	0.000836	CcSEcCtD
Famotidine—Muscle spasms—Epirubicin—pancreatic cancer	0.000587	0.00083	CcSEcCtD
Famotidine—Body temperature increased—Docetaxel—pancreatic cancer	0.000584	0.000826	CcSEcCtD
Famotidine—Abdominal pain—Docetaxel—pancreatic cancer	0.000584	0.000826	CcSEcCtD
Famotidine—Arrhythmia—Doxorubicin—pancreatic cancer	0.00058	0.00082	CcSEcCtD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.000579	0.00451	CbGpPWpGaD
Famotidine—Alopecia—Doxorubicin—pancreatic cancer	0.000573	0.000811	CcSEcCtD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000569	0.00443	CbGpPWpGaD
Famotidine—Mental disorder—Doxorubicin—pancreatic cancer	0.000568	0.000804	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—SCT—pancreatic cancer	0.000567	0.00441	CbGpPWpGaD
Famotidine—Anaemia—Epirubicin—pancreatic cancer	0.000564	0.000798	CcSEcCtD
Famotidine—Agitation—Epirubicin—pancreatic cancer	0.000561	0.000794	CcSEcCtD
Famotidine—Dysgeusia—Doxorubicin—pancreatic cancer	0.000553	0.000783	CcSEcCtD
Famotidine—Syncope—Epirubicin—pancreatic cancer	0.000547	0.000775	CcSEcCtD
Famotidine—Leukopenia—Epirubicin—pancreatic cancer	0.000546	0.000773	CcSEcCtD
Famotidine—Back pain—Doxorubicin—pancreatic cancer	0.000546	0.000773	CcSEcCtD
Famotidine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000544	0.00077	CcSEcCtD
Famotidine—Muscle spasms—Doxorubicin—pancreatic cancer	0.000543	0.000768	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—CCK—pancreatic cancer	0.00054	0.00421	CbGpPWpGaD
Famotidine—Palpitations—Epirubicin—pancreatic cancer	0.000539	0.000763	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.000538	0.00419	CbGpPWpGaD
Famotidine—Loss of consciousness—Epirubicin—pancreatic cancer	0.000537	0.000759	CcSEcCtD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	0.000534	0.00416	CbGpPWpGaD
Famotidine—Cough—Epirubicin—pancreatic cancer	0.000533	0.000754	CcSEcCtD
Famotidine—Asthenia—Docetaxel—pancreatic cancer	0.00053	0.00075	CcSEcCtD
Famotidine—Convulsion—Epirubicin—pancreatic cancer	0.000529	0.000748	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—CNR2—pancreatic cancer	0.000527	0.0041	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—GLP1R—pancreatic cancer	0.000527	0.0041	CbGpPWpGaD
Famotidine—Pruritus—Docetaxel—pancreatic cancer	0.000523	0.000739	CcSEcCtD
Famotidine—Anaemia—Doxorubicin—pancreatic cancer	0.000522	0.000739	CcSEcCtD
Famotidine—Chest pain—Epirubicin—pancreatic cancer	0.00052	0.000735	CcSEcCtD
Famotidine—Myalgia—Epirubicin—pancreatic cancer	0.00052	0.000735	CcSEcCtD
Famotidine—Arthralgia—Epirubicin—pancreatic cancer	0.00052	0.000735	CcSEcCtD
Famotidine—Agitation—Doxorubicin—pancreatic cancer	0.000519	0.000735	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—CCKAR—pancreatic cancer	0.000518	0.00404	CbGpPWpGaD
Famotidine—Anxiety—Epirubicin—pancreatic cancer	0.000518	0.000733	CcSEcCtD
Famotidine—Dry mouth—Epirubicin—pancreatic cancer	0.000508	0.000719	CcSEcCtD
Famotidine—Syncope—Doxorubicin—pancreatic cancer	0.000507	0.000717	CcSEcCtD
Famotidine—Leukopenia—Doxorubicin—pancreatic cancer	0.000506	0.000715	CcSEcCtD
Famotidine—Diarrhoea—Docetaxel—pancreatic cancer	0.000505	0.000715	CcSEcCtD
Famotidine—Confusional state—Epirubicin—pancreatic cancer	0.000502	0.000711	CcSEcCtD
Famotidine—Palpitations—Doxorubicin—pancreatic cancer	0.000499	0.000706	CcSEcCtD
Famotidine—Oedema—Epirubicin—pancreatic cancer	0.000498	0.000705	CcSEcCtD
Famotidine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000498	0.000705	CcSEcCtD
Famotidine—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000496	0.000702	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.000496	0.00387	CbGpPWpGaD
Famotidine—Infection—Epirubicin—pancreatic cancer	0.000495	0.0007	CcSEcCtD
Famotidine—Cough—Doxorubicin—pancreatic cancer	0.000493	0.000697	CcSEcCtD
Famotidine—Shock—Epirubicin—pancreatic cancer	0.00049	0.000694	CcSEcCtD
Famotidine—Convulsion—Doxorubicin—pancreatic cancer	0.000489	0.000693	CcSEcCtD
Famotidine—Dizziness—Docetaxel—pancreatic cancer	0.000488	0.000691	CcSEcCtD
Famotidine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000488	0.00069	CcSEcCtD
Famotidine—Myalgia—Doxorubicin—pancreatic cancer	0.000481	0.00068	CcSEcCtD
Famotidine—Arthralgia—Doxorubicin—pancreatic cancer	0.000481	0.00068	CcSEcCtD
Famotidine—Chest pain—Doxorubicin—pancreatic cancer	0.000481	0.00068	CcSEcCtD
Famotidine—Anxiety—Doxorubicin—pancreatic cancer	0.000479	0.000678	CcSEcCtD
Famotidine—Anorexia—Epirubicin—pancreatic cancer	0.000475	0.000672	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—SHH—pancreatic cancer	0.000472	0.00368	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PRLHR—pancreatic cancer	0.000471	0.00367	CbGpPWpGaD
Famotidine—Dry mouth—Doxorubicin—pancreatic cancer	0.00047	0.000665	CcSEcCtD
Famotidine—Vomiting—Docetaxel—pancreatic cancer	0.00047	0.000665	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—IAPP—pancreatic cancer	0.000467	0.00363	CbGpPWpGaD
Famotidine—Rash—Docetaxel—pancreatic cancer	0.000466	0.000659	CcSEcCtD
Famotidine—Dermatitis—Docetaxel—pancreatic cancer	0.000465	0.000658	CcSEcCtD
Famotidine—Confusional state—Doxorubicin—pancreatic cancer	0.000465	0.000658	CcSEcCtD
Famotidine—Headache—Docetaxel—pancreatic cancer	0.000463	0.000655	CcSEcCtD
Famotidine—Oedema—Doxorubicin—pancreatic cancer	0.000461	0.000652	CcSEcCtD
Famotidine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000461	0.000652	CcSEcCtD
Famotidine—Infection—Doxorubicin—pancreatic cancer	0.000458	0.000648	CcSEcCtD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.000457	0.00356	CbGpPWpGaD
Famotidine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000454	0.000642	CcSEcCtD
Famotidine—Shock—Doxorubicin—pancreatic cancer	0.000454	0.000642	CcSEcCtD
Famotidine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000451	0.000639	CcSEcCtD
Famotidine—Insomnia—Epirubicin—pancreatic cancer	0.000451	0.000638	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—PTHLH—pancreatic cancer	0.000448	0.00349	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—PTCH1—pancreatic cancer	0.000448	0.00349	CbGpPWpGaD
Famotidine—Paraesthesia—Epirubicin—pancreatic cancer	0.000447	0.000633	CcSEcCtD
Famotidine—Somnolence—Epirubicin—pancreatic cancer	0.000443	0.000627	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000441	0.00343	CbGpPWpGaD
Famotidine—Anorexia—Doxorubicin—pancreatic cancer	0.000439	0.000622	CcSEcCtD
Famotidine—Nausea—Docetaxel—pancreatic cancer	0.000439	0.000621	CcSEcCtD
Famotidine—Dyspepsia—Epirubicin—pancreatic cancer	0.000439	0.000621	CcSEcCtD
Famotidine—Decreased appetite—Epirubicin—pancreatic cancer	0.000433	0.000613	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—GDI2—pancreatic cancer	0.000431	0.00336	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GDI1—pancreatic cancer	0.000431	0.00336	CbGpPWpGaD
Famotidine—Fatigue—Epirubicin—pancreatic cancer	0.00043	0.000608	CcSEcCtD
Famotidine—Pain—Epirubicin—pancreatic cancer	0.000426	0.000603	CcSEcCtD
Famotidine—Constipation—Epirubicin—pancreatic cancer	0.000426	0.000603	CcSEcCtD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000423	0.0033	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000422	0.00329	CbGpPWpGaD
Famotidine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.00042	0.000594	CcSEcCtD
Famotidine—Insomnia—Doxorubicin—pancreatic cancer	0.000417	0.00059	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—PPY—pancreatic cancer	0.000414	0.00323	CbGpPWpGaD
Famotidine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000414	0.000586	CcSEcCtD
Famotidine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000411	0.000581	CcSEcCtD
Famotidine—Somnolence—Doxorubicin—pancreatic cancer	0.00041	0.00058	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—SST—pancreatic cancer	0.00041	0.00319	CbGpPWpGaD
Famotidine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000407	0.000576	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000407	0.00317	CbGpPWpGaD
Famotidine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000406	0.000574	CcSEcCtD
Famotidine—Decreased appetite—Doxorubicin—pancreatic cancer	0.000401	0.000567	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—SSTR3—pancreatic cancer	0.0004	0.00312	CbGpPWpGaD
Famotidine—Fatigue—Doxorubicin—pancreatic cancer	0.000397	0.000562	CcSEcCtD
Famotidine—Urticaria—Epirubicin—pancreatic cancer	0.000396	0.00056	CcSEcCtD
Famotidine—Pain—Doxorubicin—pancreatic cancer	0.000394	0.000558	CcSEcCtD
Famotidine—Constipation—Doxorubicin—pancreatic cancer	0.000394	0.000558	CcSEcCtD
Famotidine—Body temperature increased—Epirubicin—pancreatic cancer	0.000394	0.000557	CcSEcCtD
Famotidine—Abdominal pain—Epirubicin—pancreatic cancer	0.000394	0.000557	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000393	0.00306	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—SSTR1—pancreatic cancer	0.000384	0.00299	CbGpPWpGaD
Famotidine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.00038	0.000538	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—CNR1—pancreatic cancer	0.000378	0.00294	CbGpPWpGaD
Famotidine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000377	0.000533	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—PPY—pancreatic cancer	0.000376	0.00293	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—SSTR2—pancreatic cancer	0.000369	0.00288	CbGpPWpGaD
Famotidine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000367	0.000519	CcSEcCtD
Famotidine—Urticaria—Doxorubicin—pancreatic cancer	0.000366	0.000518	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—GCG—pancreatic cancer	0.000365	0.00284	CbGpPWpGaD
Famotidine—Body temperature increased—Doxorubicin—pancreatic cancer	0.000364	0.000516	CcSEcCtD
Famotidine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000364	0.000516	CcSEcCtD
Famotidine—Asthenia—Epirubicin—pancreatic cancer	0.000357	0.000506	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—CCKBR—pancreatic cancer	0.000357	0.00278	CbGpPWpGaD
Famotidine—Pruritus—Epirubicin—pancreatic cancer	0.000352	0.000499	CcSEcCtD
Famotidine—HRH2—GPCR ligand binding—AGTR1—pancreatic cancer	0.000348	0.00271	CbGpPWpGaD
Famotidine—Diarrhoea—Epirubicin—pancreatic cancer	0.000341	0.000482	CcSEcCtD
Famotidine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00034	0.000481	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—GAST—pancreatic cancer	0.000338	0.00263	CbGpPWpGaD
Famotidine—Asthenia—Doxorubicin—pancreatic cancer	0.000331	0.000468	CcSEcCtD
Famotidine—Dizziness—Epirubicin—pancreatic cancer	0.000329	0.000466	CcSEcCtD
Famotidine—Pruritus—Doxorubicin—pancreatic cancer	0.000326	0.000462	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—SCT—pancreatic cancer	0.00032	0.00249	CbGpPWpGaD
Famotidine—Vomiting—Epirubicin—pancreatic cancer	0.000317	0.000448	CcSEcCtD
Famotidine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000315	0.000446	CcSEcCtD
Famotidine—Rash—Epirubicin—pancreatic cancer	0.000314	0.000445	CcSEcCtD
Famotidine—Dermatitis—Epirubicin—pancreatic cancer	0.000314	0.000444	CcSEcCtD
Famotidine—Headache—Epirubicin—pancreatic cancer	0.000312	0.000442	CcSEcCtD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000309	0.00241	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GAST—pancreatic cancer	0.000307	0.00239	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CCK—pancreatic cancer	0.000305	0.00238	CbGpPWpGaD
Famotidine—Dizziness—Doxorubicin—pancreatic cancer	0.000305	0.000431	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—CNR2—pancreatic cancer	0.000298	0.00232	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000298	0.00232	CbGpPWpGaD
Famotidine—CYP2C19—Arachidonic acid metabolism—PTGS2—pancreatic cancer	0.000296	0.00231	CbGpPWpGaD
Famotidine—Nausea—Epirubicin—pancreatic cancer	0.000296	0.000419	CcSEcCtD
Famotidine—Vomiting—Doxorubicin—pancreatic cancer	0.000293	0.000415	CcSEcCtD
Famotidine—HRH2—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000293	0.00228	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—SCT—pancreatic cancer	0.000291	0.00226	CbGpPWpGaD
Famotidine—Rash—Doxorubicin—pancreatic cancer	0.000291	0.000411	CcSEcCtD
Famotidine—Dermatitis—Doxorubicin—pancreatic cancer	0.00029	0.000411	CcSEcCtD
Famotidine—Headache—Doxorubicin—pancreatic cancer	0.000289	0.000409	CcSEcCtD
Famotidine—HRH2—Signaling Pathways—PRLHR—pancreatic cancer	0.000278	0.00217	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCK—pancreatic cancer	0.000277	0.00216	CbGpPWpGaD
Famotidine—Nausea—Doxorubicin—pancreatic cancer	0.000274	0.000387	CcSEcCtD
Famotidine—HRH2—Signaling by GPCR—CNR2—pancreatic cancer	0.00027	0.00211	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GLP1R—pancreatic cancer	0.00027	0.00211	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCKAR—pancreatic cancer	0.000266	0.00207	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—IAPP—pancreatic cancer	0.000264	0.00205	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ACVR1B—pancreatic cancer	0.000261	0.00204	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—ZNRF3—pancreatic cancer	0.000261	0.00204	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000253	0.00197	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—SHH—pancreatic cancer	0.000242	0.00189	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IAPP—pancreatic cancer	0.000239	0.00186	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SSTR3—pancreatic cancer	0.000236	0.00184	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—DTX1—pancreatic cancer	0.000236	0.00184	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—SST—pancreatic cancer	0.000231	0.0018	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PTHLH—pancreatic cancer	0.00023	0.00179	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PTCH1—pancreatic cancer	0.00023	0.00179	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SSTR1—pancreatic cancer	0.000227	0.00177	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PPY—pancreatic cancer	0.000222	0.00173	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SSTR2—pancreatic cancer	0.000218	0.0017	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000215	0.00167	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CNR1—pancreatic cancer	0.000214	0.00166	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCKBR—pancreatic cancer	0.000211	0.00164	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—SST—pancreatic cancer	0.00021	0.00164	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.00021	0.00163	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GCG—pancreatic cancer	0.000206	0.00161	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—DTX4—pancreatic cancer	0.000198	0.00154	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GLI1—pancreatic cancer	0.000198	0.00154	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000197	0.00153	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CNR1—pancreatic cancer	0.000194	0.00151	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NRP1—pancreatic cancer	0.000193	0.0015	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000193	0.0015	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GCG—pancreatic cancer	0.000187	0.00146	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HEY2—pancreatic cancer	0.000185	0.00144	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GAST—pancreatic cancer	0.000181	0.00141	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—AGTR1—pancreatic cancer	0.000179	0.00139	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PRSS1—pancreatic cancer	0.000177	0.00138	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SCT—pancreatic cancer	0.000172	0.00134	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HEY1—pancreatic cancer	0.000172	0.00134	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCK—pancreatic cancer	0.000164	0.00128	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CNR2—pancreatic cancer	0.00016	0.00124	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GLP1R—pancreatic cancer	0.00016	0.00124	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CXCL8—pancreatic cancer	0.00016	0.00124	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCKAR—pancreatic cancer	0.000157	0.00122	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ARG2—pancreatic cancer	0.000153	0.00119	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—JAG2—pancreatic cancer	0.000152	0.00119	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MEN1—pancreatic cancer	0.00015	0.00117	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SHH—pancreatic cancer	0.000143	0.00112	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOTCH4—pancreatic cancer	0.000142	0.00111	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IAPP—pancreatic cancer	0.000141	0.0011	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTCH1—pancreatic cancer	0.000136	0.00106	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTHLH—pancreatic cancer	0.000136	0.00106	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TYMP—pancreatic cancer	0.000134	0.00104	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SST—pancreatic cancer	0.000124	0.000967	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000122	0.000954	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—JAG1—pancreatic cancer	0.000122	0.000946	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOTCH3—pancreatic cancer	0.000121	0.000943	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CNR1—pancreatic cancer	0.000115	0.000893	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000111	0.000866	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GCG—pancreatic cancer	0.000111	0.000862	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GLP1R—pancreatic cancer	0.000108	0.00084	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000108	0.000839	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—DPYD—pancreatic cancer	0.000106	0.000826	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AGTR1—pancreatic cancer	0.000106	0.000822	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—STK11—pancreatic cancer	0.000104	0.00081	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SLC2A2—pancreatic cancer	0.000101	0.000784	CbGpPWpGaD
Famotidine—SLC22A2—Transmission across Chemical Synapses—HRAS—pancreatic cancer	9.94e-05	0.000774	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PRSS1—pancreatic cancer	9.88e-05	0.00077	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CD—pancreatic cancer	9.78e-05	0.000761	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CB—pancreatic cancer	9.38e-05	0.000731	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SMAD4—pancreatic cancer	9.11e-05	0.00071	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CXCL8—pancreatic cancer	9.02e-05	0.000702	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HES1—pancreatic cancer	8.9e-05	0.000693	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ARG2—pancreatic cancer	8.57e-05	0.000667	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CB—pancreatic cancer	8.52e-05	0.000664	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CXCL8—pancreatic cancer	8.19e-05	0.000638	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TERT—pancreatic cancer	7.8e-05	0.000607	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CD44—pancreatic cancer	7.8e-05	0.000607	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—HRAS—pancreatic cancer	7.62e-05	0.000593	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TYMP—pancreatic cancer	7.49e-05	0.000583	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GCG—pancreatic cancer	7.48e-05	0.000582	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HIF1A—pancreatic cancer	7.46e-05	0.000581	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TSC2—pancreatic cancer	7.44e-05	0.000579	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—APOE—pancreatic cancer	7.28e-05	0.000567	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KDR—pancreatic cancer	7.13e-05	0.000555	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—STK11—pancreatic cancer	7.03e-05	0.000547	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NFKBIA—pancreatic cancer	6.78e-05	0.000528	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NOTCH1—pancreatic cancer	6.72e-05	0.000523	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CG—pancreatic cancer	6.57e-05	0.000512	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—NRAS—pancreatic cancer	6.57e-05	0.000512	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EGF—pancreatic cancer	6.49e-05	0.000506	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	6.18e-05	0.000481	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—TYMS—pancreatic cancer	6.05e-05	0.000471	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GLP1R—pancreatic cancer	6.04e-05	0.00047	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—EGFR—pancreatic cancer	5.99e-05	0.000466	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—DPYD—pancreatic cancer	5.94e-05	0.000463	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CD—pancreatic cancer	5.78e-05	0.00045	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.72e-05	0.000446	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—KRAS—pancreatic cancer	5.65e-05	0.00044	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	5.64e-05	0.000439	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.58e-05	0.000434	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.38e-05	0.000419	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PIK3CA—pancreatic cancer	5.19e-05	0.000405	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CB—pancreatic cancer	5.03e-05	0.000392	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—APOE—pancreatic cancer	4.92e-05	0.000383	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.9e-05	0.000382	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCL8—pancreatic cancer	4.84e-05	0.000377	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—HRAS—pancreatic cancer	4.81e-05	0.000374	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—AKT1—pancreatic cancer	4.67e-05	0.000364	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CASP3—pancreatic cancer	4.63e-05	0.000361	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCND1—pancreatic cancer	4.51e-05	0.000351	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CTNNB1—pancreatic cancer	4.46e-05	0.000348	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CG—pancreatic cancer	4.44e-05	0.000346	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MMP9—pancreatic cancer	4.38e-05	0.000341	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CD44—pancreatic cancer	4.36e-05	0.00034	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTEN—pancreatic cancer	4.35e-05	0.000339	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PPARG—pancreatic cancer	4.28e-05	0.000334	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.27e-05	0.000333	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—AKT1—pancreatic cancer	4.24e-05	0.000331	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.23e-05	0.00033	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GCG—pancreatic cancer	4.18e-05	0.000326	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SRC—pancreatic cancer	4.03e-05	0.000314	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—STK11—pancreatic cancer	3.93e-05	0.000306	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—VEGFA—pancreatic cancer	3.93e-05	0.000306	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CD—pancreatic cancer	3.9e-05	0.000304	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—STAT3—pancreatic cancer	3.89e-05	0.000303	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—NRAS—pancreatic cancer	3.88e-05	0.000302	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.69e-05	0.000288	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MYC—pancreatic cancer	3.62e-05	0.000282	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TGFB1—pancreatic cancer	3.61e-05	0.000281	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—EGFR—pancreatic cancer	3.54e-05	0.000275	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	3.4e-05	0.000265	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—TYMS—pancreatic cancer	3.38e-05	0.000264	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PTGS2—pancreatic cancer	3.37e-05	0.000262	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—KRAS—pancreatic cancer	3.34e-05	0.00026	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PIK3CA—pancreatic cancer	3.07e-05	0.000239	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TP53—pancreatic cancer	2.97e-05	0.000231	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PTEN—pancreatic cancer	2.94e-05	0.000229	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—HRAS—pancreatic cancer	2.84e-05	0.000221	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—APOE—pancreatic cancer	2.75e-05	0.000214	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.61e-05	0.000203	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—AKT1—pancreatic cancer	2.51e-05	0.000195	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	2.48e-05	0.000193	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PPARG—pancreatic cancer	2.4e-05	0.000187	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	2.18e-05	0.00017	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	2.07e-05	0.000161	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.9e-05	0.000148	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.89e-05	0.000147	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—AKT1—pancreatic cancer	1.69e-05	0.000132	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.64e-05	0.000128	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	1.16e-05	9.04e-05	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—AKT1—pancreatic cancer	9.48e-06	7.38e-05	CbGpPWpGaD
